论文部分内容阅读
目的观察5-氟尿嘧啶和顺铂(FP)联合艾迪注射液联合~(125)I粒子植入治疗中晚期原发性肝癌的临床疗效。方法以唐山市人民医院2012年2月至2015年7月收治的原发性肝癌患者95例作为研究对象,按随机数表法分为观察组(n=50)和对照组(n=45)。对照组患者采取FP联合~(125)I粒子植入治疗,观察组在对照组基础上联合艾迪注射液进行治疗,时间2个疗程。比较两组患者临床缓解率、治疗前后KPS评分、外周血白细胞计数、不良反应发生率,以及1年和2年生存率。结果治疗后,观察组患者的临床缓解率为36.0%,明显高于对照组的17.8%,差异有统计学意义(P<0.05);观察组与对照组患者治疗前的KPS评分分别为(72.2±4.1)分、(72.4±4.4)分,外周血白细胞计数分别为(6.3±1.9)×10~9/L、(6.1±2.2)×10~9/L,组间比较差异均无统计学意义(P>0.05);治疗后,观察组与对照组患者的KPS评分分别升高至(85.3±5.0)分、(79.3±5.2)分,外周血白细胞计数分别减少至(5.0±1.6)×10~9/L、(3.1±1.3)×10~9/L,较治疗前均改善明显,且观察组治疗后的KPS评分、外周血白细胞计数均高于对照组,差异均有统计学意义(P<0.05)。结论 FP+艾迪注射液联合~(125)I粒子植入治疗中晚期原发性肝癌能明显提高临床缓解率与KPS评分,抑制白细胞减少,生存时间得以延长,值得临床推广应用。
Objective To observe the clinical efficacy of 5-fluorouracil and cisplatin (FP) in combination with Aidi injection and 125 I seed implantation in the treatment of advanced primary liver cancer. Methods Ninety-five patients with primary liver cancer admitted from February 2012 to July 2015 in Tangshan People’s Hospital were divided into observation group (n = 50) and control group (n = 45) according to random number table method. . Patients in the control group were treated with FP combined with (125) I seed implantation. The observation group was treated with Aidi Injection on the basis of the control group for two courses of treatment. The clinical remission rate, KPS score, peripheral blood leukocyte count, incidence of adverse reactions, and 1-year and 2-year survival rates were compared between the two groups. Results After treatment, the clinical remission rate in the observation group was 36.0%, which was significantly higher than that in the control group (17.8%, P <0.05). The KPS scores of the observation group and the control group before treatment were (72.2% ± 4.1) points and (72.4 ± 4.4) points respectively. The peripheral blood leukocyte counts were (6.3 ± 1.9) × 10 ~ 9 / L and (6.1 ± 2.2) × 10 ~ 9 / L respectively. There was no significant difference between the two groups (P <0.05). After treatment, the KPS scores of the observation group and the control group increased to (85.3 ± 5.0) and (79.3 ± 5.2) points respectively, and the peripheral blood leukocyte count decreased to (5.0 ± 1.6) × 10 ~ 9 / L and (3.1 ± 1.3) × 10 ~ 9 / L, respectively. Compared with those before treatment, the KPS score and peripheral blood leukocyte count in the observation group were significantly higher than those in the control group (P <0.05). Conclusion FP + Aidi injection combined with ~ (125) I seed implantation in the treatment of advanced primary liver cancer can significantly improve clinical remission rate and KPS score, inhibit leukopenia and prolong survival time, which is worthy of clinical application.